Ginkgo Bioworks DNA Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -210.7%-7.1pp | -192%+54.6pp | -199.5%+91.5pp | -138.3%+331pp | -203.5%+193pp | |
| Net margin | -215.4%-7.7pp | -195.4%+45.5pp | -199.1%+99.7pp | -142.8%+344pp | -207.7%+201pp | |
| EBITDA margin | -170.3%+4.6pp | -155.1%+63.7pp | -163.7%+99.7pp | -109.3%+325pp | -175%+190pp | |
| Free cash flow margin | -119%+32.9pp | -111.7%+56.6pp | -109.8%+67.9pp | -124.2%+63.8pp | -151.9%+2.5pp | |
| Returns | ||||||
| Return on equity | -55.8%+1.9pp | -51.1%+9.3pp | -50%+13.5pp | -43.6%+33.2pp | -57.8%+8.1pp | |
| Return on assets | -26.2%+6.7pp | -25%+10.9pp | -25.4%+11.7pp | -22.1%+23.8pp | -32.8%+9.9pp | |
| Return on invested capital | -42.8%+44.4pp | -46.8%+73.9pp | -48.3%+62.6pp | -57%+112pp | -87.2%+64.8pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.2×+0.1× | 0.2×+0.1× | |
| Liquidity | ||||||
| Current ratio | 5.2×+0.3× | 4.9×-0.7× | 4.4×-1.4× | 5.4×+0.7× | 4.9×-0.5× | |
| Quick ratio | 5.2×+0.3× | 4.9×-0.7× | 4.4×-1.4× | 5.4×+0.7× | 4.9×-0.5× | |
| Cash ratio | 2.4×-0.7× | 2.2×-3.4× | 1.4×-4.4× | 2.6×-2.1× | 3.1×-2.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.9×+0.3× | 0.9×+0.2× | 0.8×+0.2× | 0.7×+0.4× | 0.7×+0.4× | |
| Debt-to-assets | 0.4×+0.1× | 0.4×+0.1× | 0.4×+0.1× | 0.3×+0.2× | 0.3×+0.2× | |
| Valuation | ||||||
| Market capitalization | $625.16M+24.6% | $503.5M-10.8% | $863.13M+90.6% | $537.91M-27.2% | $330.79M-86.8% | |
| Enterprise value | $847.19M+45.9% | $731.02M+71.4% | $1.13B+376% | $715.38M+282% | $409.95M-77.8% | |
| Price / sales | 4.4×+2.2× | 3.1×+0.7× | 5.1×+3.0× | 2.4×-1.6× | 1.5×-10.5× | |
| Price / book | 1.4×+0.6× | 1×+0.2× | 1.5×+1.0× | 0.9×0.0× | 0.5×-2.0× | |
| EV / sales | 6×+3.4× | 4.6×+2.7× | 6.6×+5.5× | 3.2×+2.2× | 1.8×-7.0× | |
| Free cash flow yield | -26.9%+41.9pp | -35.5%+32.2pp | -21.7%+63.8pp | -51%-4.1pp | -104.4%-91.5pp | |
| Earnings yield | -48.7%+45.4pp | -62.1%+34.8pp | -39.3%+104pp | -58.6%+62.8pp | -142.7%-109pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Ginkgo Bioworks's ratios come from?
- Every ratio is computed from Ginkgo Bioworks's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
